4.6.0.0 Pan­cre­ati­tis

Rec­om­men­da­tion

4.15 Islet au­to­trans­plan­ta­tion should be con­sid­ered for pa­tients re­quir­ing total pan­cre­a­te­c­to­my for med­i­cally re­frac­to­ry chron­ic pan­cre­ati­tis to pre­vent post­sur­gi­cal di­a­betes. C

Di­a­betes is linked to dis­eases of the ex­ocrine pan­creas such as pan­cre­ati­tis, which may dis­rupt the glob­al ar­chi­tec­ture or phys­i­ol­o­gy of the pan­creas, often re­sulting in both ex­ocrine and en­docrine dysfunc­tion. Up to half of pa­tients with di­a­betes may have im­paired ex­ocrine pan­creas func­tion (51). Peo­ple with di­a­betes are at an ap­prox­i­mate­ly twofold high­er risk of de­vel­oping acute pan­cre­ati­tis (52).

Con­verse­ly, predi­a­betes and/‍or di­a­betes has been found to de­vel­op in ap­prox­i­mate­ly one-‍third of pa­tients after an episode of acute pan­cre­ati­tis (53), thus the re­la­tion­ship is like­ly bidi­rec­tion­al. Postpan­cre­ati­tis di­a­betes may in­clude ei­ther new-‍onset dis­ease or pre­vi­ously un­rec­og­nized di­a­betes (54). Stud­ies of pa­tients treat­ed with in­cretin-‍based ther­a­pies for di­a­betes have also re­ported that pan­cre­ati­tis may occur more fre­quent­ly with these med­i­ca­tions, but re­sults have been mixed (55,56).

Islet au­to­trans­plan­ta­tion should be con­sid­ered for pa­tients re­quir­ing total pan­cre­a­te­c­to­my for med­i­cally re­frac­to­ry chron­ic pan­cre­ati­tis to pre­vent post­sur­gi­cal di­a­betes. Ap­prox­i­mate­ly one-‍third of pa­tients un­der­going total pan­cre­a­te­c­to­my with islet au­to­trans­plan­ta­tion are in­sulin free 1 year post­op­er­a­tive­ly, and ob­ser­va­tion­al stud­ies from dif­fer­ent cen­ters have demon­strat­ed islet graft func­tion up to a decade after the surgery in some pa­tients (57–61). Both pa­tient and dis­ease fac­tors should be care­ful­ly con­sid­ered when de­cid­ing the in­di­ca­tions and tim­ing of this surgery. Surg­eries should be per­formed in skilled fa­cil­i­ties that have demon­strat­ed ex­pertise in islet au­to­trans­plan­ta­tion.